Giant invasive prolactinomas.
Two of the largest prolactinomas ever documented that have been followed for nine and 10 years, respectively, demonstrate how aggressive prolactinomas may become and how difficult invasive prolactinomas are to treat. One of these prolactinomas invaded both internal auditory canals and simultaneously grew inferiorly, reducing the bony support of the skull and necessitating the patient to utilize both hands to hold his head up. The second patient's prolactinoma invaded the sphenoidal, ethmoidal, and cavernous sinuses. Both of these patients had neurosurgical debulking of their tumors followed by radiation therapy. Neither patient's prolactin levels decreased significantly during their first five years post-surgically, at which time bromocriptine was added. Since then, there has been a gradual lowering of serum prolactin levels and a decrease in the size of these tumors. These cases demonstrate that prolonged treatment and very large doses of bromocriptine may be necessary for tumor reduction in patients with invasive prolactinomas.
Murphy
F Y
FY
Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock.
Vesely
D L
DL
Jordan
R M
RM
Flanigan
S
S
Kohler
P O
PO
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D007758:Ear, Inner / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010256:Paranasal Sinuses / Q000473:pathology; D010902:Pituitary Gland / Q000473:pathology*; D010911:Pituitary Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D011388:Prolactin / Q000378:metabolism*; D014057:Tomography, X-Ray Computed
D003037:Cobalt Radioisotopes; D001971:Bromocriptine; D011388:Prolactin